{"id":47682,"date":"2024-04-05T07:40:25","date_gmt":"2024-04-05T07:40:25","guid":{"rendered":"https:\/?p=47682"},"modified":"2024-04-05T07:40:25","modified_gmt":"2024-04-05T07:40:25","slug":"abbvie-stock-drops-as-the-company-cuts-profit-forecasts","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/","title":{"rendered":"AbbVie Stock Drops as the Company Cuts Profit Forecasts"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/ABBV\">AbbVie Inc (ABBV: NYE)<\/a><\/strong> stock price tumble over 5.3% on Thursday, April 4th, following a downward revision to the company&#8217;s earnings per share (EPS) outlook for both the first quarter and full year of 2024.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Key Reasons behind AbbVie&#8217;s Stock Price Drops:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Following an adjustment in its first-quarter EPS estimate from the earlier $2.26 to $2.30 range to $2.18 \u2013 $2.22, investor sentiment regarding AbbVie faltered. This $0.08 per share negative impact came in light of acquired IP&amp;R&amp;D expenses incurred through the ImmunoGen acquisition. AbbVie lowered its first-quarter guidance by $0.04 per share in February 2024, primarily due to the dilutive effects of the same deal.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">An additional blow came as AbbVie\u2019s full-year EPS outlook also took a hit. The forecast dropped to $10.97 \u2013 $11.17, down from the prior $11.05 \u2013 $11.25 range, as a result of a projected $0.42 per share dilutive effect also tied to the ImmunoGen acquisition.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Stock Target Advisor\u2019s View on AbbVie&#8217;s Future:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Stock Target Advisor recommends AbbVie with a &#8216;Buy&#8217; rating. Although the average analyst target price for AbbVie Inc. is $176.07 over the next 12 months, reflecting a &#8216;Strong Buy&#8217; rating from 10 analysts. This opinion reasonably takes into account both encouraging and deterrent signals.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/ABBV\" target=\"_blank\" rel=\"noopener\">ABBV Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"ABBV\" data-theme=\"wt_bg_trans\" data-uid=\"856020920660f9e1a9850e660f9e1a98510\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<p><span style=\"font-weight: 400;\">Although other stocks in the sector, such as Eli Lilly and Company (LLY), Johnson &amp; Johnson (JNJ), Merck &amp; Company Inc (MRK), and Novartis AG ADR (NVS), sport significant achievements, AbbVie remains a viable choice for many investors.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Conclusion:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">AbbVie&#8217;s decision to trim its EPS outlook shook the markets, but it&#8217;s crucial for investors to remember that these revisions are part and parcel of dynamic business operations, particularly in the highly competitive pharma industry. <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc (ABBV: NYE) stock price tumble over 5.3% on Thursday, April 4th, following a downward revision to the company&#8217;s earnings per share (EPS) outlook&#8230;<\/p>\n","protected":false},"author":17,"featured_media":36508,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AbbVie Stock Drops as the Company Cuts Profit Forecasts<\/title>\n<meta name=\"description\" content=\"AbbVie (ABBV: NYE) cuts EPS outlook for Q1 &amp; 2024 due to ImmunoGen deal. Stock price falls over 5% on downgraded earnings guidance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Stock Drops as the Company Cuts Profit Forecasts\" \/>\n<meta property=\"og:description\" content=\"AbbVie (ABBV: NYE) cuts EPS outlook for Q1 &amp; 2024 due to ImmunoGen deal. Stock price falls over 5% on downgraded earnings guidance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-05T07:40:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/07\/STA-Banner-5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"AbbVie Stock Drops as the Company Cuts Profit Forecasts\",\"datePublished\":\"2024-04-05T07:40:25+00:00\",\"dateModified\":\"2024-04-05T07:40:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\"},\"wordCount\":280,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\",\"name\":\"AbbVie Stock Drops as the Company Cuts Profit Forecasts\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-04-05T07:40:25+00:00\",\"dateModified\":\"2024-04-05T07:40:25+00:00\",\"description\":\"AbbVie (ABBV: NYE) cuts EPS outlook for Q1 & 2024 due to ImmunoGen deal. Stock price falls over 5% on downgraded earnings guidance.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Stock Drops as the Company Cuts Profit Forecasts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Stock Drops as the Company Cuts Profit Forecasts","description":"AbbVie (ABBV: NYE) cuts EPS outlook for Q1 & 2024 due to ImmunoGen deal. Stock price falls over 5% on downgraded earnings guidance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie Stock Drops as the Company Cuts Profit Forecasts","og_description":"AbbVie (ABBV: NYE) cuts EPS outlook for Q1 & 2024 due to ImmunoGen deal. Stock price falls over 5% on downgraded earnings guidance.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-04-05T07:40:25+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/07\/STA-Banner-5.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"AbbVie Stock Drops as the Company Cuts Profit Forecasts","datePublished":"2024-04-05T07:40:25+00:00","dateModified":"2024-04-05T07:40:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/"},"wordCount":280,"commentCount":1,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/","name":"AbbVie Stock Drops as the Company Cuts Profit Forecasts","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-04-05T07:40:25+00:00","dateModified":"2024-04-05T07:40:25+00:00","description":"AbbVie (ABBV: NYE) cuts EPS outlook for Q1 & 2024 due to ImmunoGen deal. Stock price falls over 5% on downgraded earnings guidance.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-stock-drops-as-the-company-cuts-profit-forecasts\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"AbbVie Stock Drops as the Company Cuts Profit Forecasts"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=47682"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47682\/revisions"}],"predecessor-version":[{"id":47684,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47682\/revisions\/47684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/36508"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=47682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=47682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=47682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}